LLY
Eli Lilly and Company
LLY has a slight edge over SUPN overall, supported by stronger fundamentals and lower modeled downside.
SUPN
Indivior Pharmaceuticals Inc
SUPN offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SUPN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Healthy |
SUPN's revenue, profitability and balance sheet are currently healthy, but its cash flow is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SUPN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.4x | $29.20 | — |
| Current | 8.2x | $29.20 | — |
| Cheap | 18x | $63.68 | +118% |
| Fair | 26x | $91.92 | +215% |
| Expensive | 97x | $347 | +1088% |
Historical ranges are pointers, not guarantees.
SUPN has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over SUPN on the outlook, with more favorable profitability expectations.
SUPN Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for SUPN, but weaker profitability. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SUPN on earnings, with more consistent year-over-year improvement.
SUPN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.97 | +11% |
| Q3 2026 | $3.58 | +175% |
| Q2 2026 | $2.79 | +179% |
| Q1 2026 | $1.95 | +1293% |
| Q4 2025 | $1.64 | +681% |
| Q3 2025 | $1.30 | +829% |
| Q2 2025 | $1.00 | +$1.83 |
| Q1 2025 | $0.14 | -18% |
| Q4 2024 | $0.21 | +425% |
SUPN earned $3.58 per share over the past year, up 175% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SUPN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
SUPN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $356M | +13% |
| Q2 2026 | $343M | +14% |
| Q1 2026 | $317M | +19% |
| Q4 2025 | $358M | +20% |
| Q3 2025 | $314M | +2.3% |
| Q2 2025 | $302M | +1% |
| Q1 2025 | $266M | -6.3% |
| Q4 2024 | $299M | +2% |
SUPN's revenue has grown year over year for six quarters in a row: $356M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 51% | +37 points |
| Q2 2026 | 47% | +23 points |
| Q1 2026 | 43% | +18 points |
| Q4 2025 | 23% | -9.5 points |
| Q3 2025 | 14% | +12 points |
| Q2 2025 | 24% | +63 points |
| Q1 2025 | 25% | -1.6 points |
| Q4 2024 | 32% | +11 points |
SUPN has the edge over LLY on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SUPN on cash flow, with more consistent year-over-year improvement.
SUPN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $83M | +$142M |
| Q2 2026 | $222M | +57% |
| Q1 2026 | -$29M | -141% |
| Q4 2025 | -$245M | -$224M |
| Q3 2025 | -$59M | -$54M |
| Q2 2025 | $141M | +68% |
| Q1 2025 | $70M | +$110M |
| Q4 2024 | -$21M | +$278M |
SUPN has burned cash in most quarters: $31M over the past year, down 76% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SUPN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -2M shares |
| 1 year | -5.4% | -7M shares |
| 3 years | -11% | -15.7M shares |
SUPN has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $177M |
| Q1 2026 | $126M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $11M |
| Q4 2024 | $51M |
SUPN spent $303M buying back its own shares over the past year, about five times what it spent the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SUPN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.7x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | 0.5x | Very low |
SUPN has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SUPN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.4 | Neutral |
| Stochastic | 32.2 | Neutral |
SUPN's weekly RSI is 40 (neutral) and its Stochastic is 32 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SUPN PE vs Healthcare Sector
| Metric | SUPN | Sector median | Relative |
|---|---|---|---|
| PE | 8.2x | 26x | 68% below |
| PE % | 1 | 29 | 28 pts below |
SUPN has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SUPN on trend strength, trading above more of its moving averages.
SUPN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.3 | 19% below |
| 20 week MA | $37.3 | 22% below |
| 50 week MA | $35.8 | 18% below |
| 100 week MA | $26.3 | 11% above |
| 200 week MA | $21.9 | 34% above |
SUPN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 34% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SUPN on returns for 2026, with the stronger performance.
SUPN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.83 | $6.90 | +144% |
| 2021 | $6.90 | $17.8 | +157% |
| 2022 | $17.8 | $22.0 | +24% |
| 2023 | $22.0 | $15.3 | -31% |
| 2024 | $15.3 | $12.4 | -19% |
| 2025 | $12.4 | $36.2 | +192% |
| 2026 YTD | $36.2 | $29.2 | -19% |
SUPN has finished higher in four of the last six years, three of them by more than 50%. It's down 19% so far in 2026.